Strategic Acquisition Serametrix became part of Caprion Biosciences, signaling a broader capabilities platform in immune monitoring and biomarker development. This integration suggests cross-sell opportunities to Caprion’s existing clients and an expanded addressable market in oncology immunotherapy.

Global Reach Operates with facilities across the Americas, Europe and China, enabling scalable, multi-region clinical trial support. Sales conversations can emphasize capabilities for global studies, standardization of assays, and rapid deployment of new biomarkers internationally.

Immuno-Oncology Focus Specializes in measuring immune responses and biomarkers related to drug response and disease progression, including expertise in MDSC analysis. This aligns with growing demand for immune monitoring in cancer therapies, presenting upsell potential to biotech and pharma clients investing in IO programs.

Clinical Trial Readiness Experience in launching assays for new biomarkers and validating customizable biomarker panels for large-scale trials. Prospects include partnering with sponsors seeking turnkey immune monitoring solutions to accelerate drug development timelines.

Strategic Partnerships Past collaborations with leading cancer research institutions and centers (e.g., Ludwig Institute, MSK) indicate a strong network in academia and industry. This can be leveraged to access co-development deals, referenceable studies, and joint go-to-market opportunities.